Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2011

View Archived Issues

New vaccine shows promise in several models of infection

Phase III data support safety of dextromethorphan hydrobromide/quinidine sulfate in MS

Trial confirms earlier results with PET imaging agent florbetaben (18F)

Ampio Pharmaceuticals presents data from first-in-human Ampion trial

New TRPV4 channel antagonists disclosed

Adventrx and FDA agree on pivotal ANX-514 trial

Anthera Pharmaceuticals completes enrollment in PEARL-SC trial

MOC-carboetomidate induces hypnosis without adrenocortical suppression

Subcutaneous and intravenous secukinumab formulations evaluated in plaque psoriasis

Novel vasopressin V1A receptor antagonists designed by Roche

New Wnt signaling inhibitors discovered in Germany

TopoTarget patents new nicotinamide phosphoribosyltransferase inhibitors

Marina Biotech presents novel nucleic acid complexes

Intellect Neurosciences initiates development of new platform technology for proteinopathies

KemPharm to develop first-in-class oral hydromorphone prodrug

New Toll-like receptor 2 agonists prepared by IRM

Researchers at Abbott claim novel inhibitors of Bcl-2

Alexza Pharmaceuticals submits MAA for Adasuve

Marshall Edwards and Ausio Pharmaceuticals enter licensing agreement for AUS-131

Neuralstem completes phase Ia trial of NSI-189 in major depressive disorder

MHRA clears MediGene's clinical formulation study of RhuDex

Gilead files NDA for antiretroviral Quad regimen

European indication of Prevenar 13 extended

European Commission extends Alimta approval

FDA clears Ventana's companion algorithm for image analysis in HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...